Sp1251
MECHANISMS FOR ESOPHAGEAL SMOOTH MUSCLE DYSFUNCTION IN EOE
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
Concomitant esophageal dysmotility can be present in up to 2/3 of patients with EoE and GERD. Esophageal dysmotility contribute to symptoms in these patients and can be a reason for a suboptimal response to therapy. Mechanisms for dysfunction of esophageal smooth muscle function in EoE and GERD have been studied in bench models of human esophageal tissues. Understanding and targeting these mechanisms therapeutically may improve symptomatic outcomes in what are otherwise considered mucosal esophageal diseases.
Concomitant esophageal dysmotility can be present in up to 2/3 of patients with EoE and GERD. Esophageal dysmotility contribute to symptoms in these patients and can be a reason for a suboptimal response to therapy. Mechanisms for dysfunction of esophageal smooth muscle function in EoE and GERD have been studied in bench models of human esophageal tissues. Understanding and targeting these mechanisms therapeutically may improve symptomatic outcomes in what are otherwise considered mucosal esophageal diseases.
Presenter
Baylor University Medical Center at Dallas
Tracks
Related Products
INTRODUCTION
SOCIETY: AGA
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PANEL DISCUSSION / Q&A
Concomitant esophageal dysmotility can be present in up to 2/3 of patients with EoE and GERD. Esophageal dysmotility contribute to symptoms in these patients and can be a reason for a suboptimal response to therapy…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
